CME online

in association with the 20th Annual World Congress on Insulin Resistance
Diabetes and Cardiovascular Disease -WCIRDC

Toward Reducing the Disease Burden of Heart Failure & Improve Patients Outcomes

This is a CME Symposium Supported by an Educational Grant from Bayer
Provided By:

Administrated by:
This CME online educational activity is approved for a maximum of 1.0 AMA PRA Category 1 Credit(s). and ABIM MOC

Accreditation period: January 20, 2025 - January 20, 2026

To get started:

Login / Register
CME information
View Agenda
Course presentation

To Receive a Certificate for This CME Activity:  

View the presentations in this CME activity and complete the evaluation. Your certificate will be mailed to you upon satisfactory completion of these documents.

Toward Reducing the Disease Burden of Heart Failure & Improve Patients Outcomes
Agenda

Introduction
Muthiah Vaduganathan, MD, MPH

Moonraker- Overview of the Investigators Led Research Program
Mikhail N. Kosiborod, MD

FINEARTS-HF - Finerenone in Heart Failure with EF > 40%
Orly Vardeny, PharmD, MS

FINE-HEART - Finerenone in Heart Failure and Chronic Kidney Disease Trials
Muthiah Vaduganathan, MD, MPH

Panel Discussion - The Crystal Ball- ns MRA in the Guidelines
Panel: : Orly Vardeny, PharmD, MS • Muthiah Vaduganathan, MD, MPH
Moderator: Mikhail N. Kosiborod, MD

Faculty

Mikhail N. Kosiborod, MD, FACC, FAHA Chair

Vice President of Research
Endowed Chair in Cardiovascular Research
Saint Luke’s Health System
Executive Director, Cardiometabolic Center Alliance
Co-Director the Haverty Cardiometabolic Center of Excellence
Saint Luke’s Mid-America Heart Institute
Professor of Medicine, University of Missouri
Kansas City, Missouri

Muthiah Vaduganathan, MD, MPH, FACC, FHFA Chair

Cardiologist and Clinical Trialist
Brigham and Women’s Hospital and Harvard Medical School Co-director
Center for Cardiometabolic Implementation Science
Boston, Massachusetts


Orly Vardeny, PharmD, MS

Professor of Medicine University of Minnesota
Minneapolis, Minnesota

Program Description

Heart Failure shares many etiologic pathways with obesity T2D, CVD, and CKD. Nearly 40% of patients with diabetes and Obesity have CKD heart failure and CVD. Currently HFpEF, for which effective treatments are limited, tracks the obesity epidemic occurs in > 50% of patients with heart failure. New treatment modalities are key to future improved outcome. In this satellite symposium will learn of new studies identifying the important role of finerenone in the treatment for HF across a broad spectrum of patients and ejection fraction. Clinician will also understand the impact of Finerenone in patients with CKD & Heart Failure.




Learning Objectives

Upon completion of this CME symposium, participants should be able to:
• Describe the goals and scope of MOONRAKER finerenone trials as a treatment for HF across a broad spectrum of patients • Know the results of FINEARTS-HF finerenone in symptomatic HF patients with an ejection fraction of ≥40%. • Understand the results of FINE-HEARTS establishing finerenone impact on patients with Heart Failure and Chronic Kidney Disease

Target Audience

This educational initiative is designed for cardiologists, nephrologists, endocrinologists, Diabetologists, primary care physicians, internists, and other healthcare professionals interested in the Epidemiology, pathophysiology of diabetes with CKD and the prevention of related morbidity and mortality.

CME Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PES Inc. is accredited by the ACCME to provide continuing medical education for physicians.
PESI, Inc, designated this live educational activity for a maximum of 1.00 AMA PRA Category 1 Credit(s).
Physicians should only claim credit commensurate with the extent of their participation in the activity.